NICE Technology Appraisals About Medicines: Formulary Adherence Checklist
Total Page:16
File Type:pdf, Size:1020Kb
NICE Technology Appraisals About Medicines: Formulary Adherence Checklist This spreadsheet enables self-audit of a medicines formulary for adherence to NICE Technology Appraisals. No copyright is asserted if used for non-commercial purposes within the NHS. Technology appraisal (TA) Date of TA Availability of medicine for NHS patients with this medical condition, as Adherence of local formulary to NICE Titles are hyperlinks to full guidance Release indicated by NICE Yes N/A Date of local Time to Notes (e.g. rationale, method of making available) (mark 'x' if (mark 'x' if decision implement applicable) applicable) (DD/MM/YY) (days) 2020-21 Naldemedine for treating opioid-induced 30/09/2020 Naldemedine ̶ recommended, within its marketing authorisation, as an option for treating opioid- TBC TBC Not on Trust formulary. Contacted Gastro, Surgical constipation (TA651) induced constipation in adults who have had laxative treatment. and Medicine teams (30/09/20). Fast track x application for Trust wide use to be completed (30/09/20). Awaiting MMC review once submitted. Pembrolizumab with axitinib for untreated 30/09/2020 Pembrolizumab with axitinib ̶ NOT RECOMMENDED within its marketing authorisation, for untreated 08/10/2020 8 Not on Trust formulary for this indication. Surgical & advanced renal cell carcinoma (TA650) advanced renal cell carcinoma in adults. Renal Teams confirmed compliance with non-use x (30/09/20). Approved by MMC and added to the formulary for this indication (08/10/20). Polatuzumab vedotin with rituximab and 23/09/2020 Polatuzumab vedotin with rituximab and bendamustine ̶ recommended as an option for treating 08/10/2020 15 Not on Trust formulary. Contacted Haematology bendamustine for treating relapsed or relapsed or refractory diffuse large B cell lymphoma in adults who cannot have a haematopoietic stem Oncology teams (23/09/20); submitted fast track cell transplant. It is recommended only if the company provides polatuzumab vedotin according to the ‑ x refractory diffuse large B-cell lymphoma commercial arrangement. application (24/09/20). Approved by MMC and (TA649) added to the formulary for this indication (08/10/20). Dupilumab for treating chronic rhinosinusitis 09/09/2020 Dupilumab ̶ NOT RECOMMENDED for treating chronic rhinosinusitis with nasal polyps because Sanofi 08/10/2020 29 Not on Trust formulary for this indication. with nasal polyps (TA648) (TERMINATED did not provide an evidence submission. The company has confirmed that it does not intend to make a Terminated appraisal by NICE. MMC deemed N/A submission for the appraisal because there is unlikely to be sufficient evidence that the technology is a x APPRAISAL) cost-effective use of NHS resources in this population. (08/10/20). Eculizumab for treating relapsing 02/09/2020 Eculizumab ̶ NOT RECOMMENDED for treating relapsing neuromyelitis optica because Alexion Pharma 10/09/2020 8 Not on Trust formulary for this indication. neuromyelitis optica (TA647) (TERMINATED UK did not provide an evidence submission. The company has confirmed that it does not intend to make a Terminated appraisal by NICE. MMC deemed N/A submission for the appraisal because the technology will not be launched in the UK for this indication. x APPRAISAL) (10/09/20). Glasdegib with chemotherapy for untreated 02/09/2020 Glasdegib ̶ NOT RECOMMENDED with chemotherapy for untreated acute myeloid leukaemia because 10/09/2020 8 Not on Trust formulary for this indication. Pfizer did not provide an evidence submission. The company has confirmed that it does not intend to acute myeloid leukaemia (TA646) x Terminated appraisal by NICE. MMC deemed N/A make a submission for the appraisal because the technology is unlikely to be a cost-effective use of NHS (TERMINATED APPRAISAL) resources. (10/09/20). Avelumab with axitinib for untreated 02/09/2020 Avelumab with axitinib ̶ recommended for use within the CDF as an option for untreated advanced renal 10/09/2020 8 Not on Trust formulary for this indication. Contacted advanced renal cell carcinoma (TA645) cell carcinoma in adults. It is recommended only if the conditions in the managed access agreement for Surgical and Renal teams (02/09/20). N/A responses avelumab with axitinib are followed. x (02/09/20). MMC approved and added to formulary for this indication - not stocked (10/09/20). Entrectinib for treating NTRK fusion-positive 12/08/2020 Entrectinib ̶ recommended for use within the CDF as an option for treating neurotrophic tyrosine 10/09/2020 29 Not on Trust formulary. Contacted Haematology solid tumours (TA644) receptor kinase (NTRK) fusion-positive solid tumours in adults and children 12 years and older if the Oncology teams (12/08/20); submitted fast track disease is locally advanced or metastatic or surgery could cause severe health problems and; they have application (12/08/20). MMC approved and added to not had an NTRK inhibitor before and; they have no satisfactory treatment options. It is recommended x only if the conditions in the managed access agreement for entrectinib are followed. formulary for this indication (10/09/20). Entrectinib for treating ROS1-positive 12/08/2020 Entrectinib ̶ recommended, within its marketing authorisation, as an option for treating ROS1-positive 10/09/2020 29 Not on Trust formulary. Contacted Respiratory advanced non-small-cell lung cancer (TA643) advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors. It is Oncology teams (12/08/20); submitted fast track recommended only if the company provides entrectinib according to the commercial arrangement. x application (12/08/20). MMC approved and added to formulary for this indication (10/09/20). Technology appraisal (TA) Date of TA Availability of medicine for NHS patients with this medical condition, as Adherence of local formulary to NICE Titles are hyperlinks to full guidance Release indicated by NICE Yes N/A Date of local Time to Notes (e.g. rationale, method of making available) (mark 'x' if (mark 'x' if decision implement applicable) applicable) (DD/MM/YY) (days) Gilteritinib for treating relapsed or refractory 12/08/2020 Gilteritinib monotherapy ̶ recommended as an option for treating relapsed or refractory FLT3 mutation- 14/05/2020 -90 On Trust formulary for this indication. Haem team positive acute myeloid leukaemia (AML) in adults only if the company provides gilteritinib according to acute myeloid leukaemia (TA642) ‑ previously submitted fast track application for the commercial arrangement. x SSC2162. MMC approved and added to formulary for this indication (14/05/20). Brentuximab vedotin in combination for 12/08/2020 Brentuximab vedotin with cyclophosphamide, doxorubicin and prednisone (CHP) ̶ recommended, within 13/08/2020 1 Not on Trust formulary for this indication. Contacted untreated systemic anaplastic large cell its marketing authorisation, as an option for untreated systemic anaplastic large cell lymphoma in adults. Haematology team (12/08/20). Haem team It is only recommended if the company provides brentuximab vedotin according to the commercial lymphoma (TA641) arrangement. x previously submitted fast track application for SSC2155. MMC approved and added to formulary for this indication (13/08/20). Treosulfan with fludarabine for malignant 05/08/2020 Treosulfan with fludarabine ̶ recommended as an option for conditioning treatment before allogeneic 10/09/2020 36 Not on Trust formulary for this indication. Contacted disease before allogeneic stem cell transplant haematopoietic stem cell transplant (allo-HSCT) for people with malignant diseases for whom a reduced Haematology team (05/08/20). Haem team intensity regimen, such as low-dose busulfan with fludarabine, would be suitable. (TA640) x submitted fast track application (05/08/20). MMC approved and added to formulary for this indication (10/09/20). Atezolizumab with nab-paclitaxel for 01/07/2020 Atezolizumab with nab paclitaxel ̶ recommended for treating triple ̶ negative, unresectable, locally 13/08/2020 43 Not on Trust formulary for this indication. Contacted advanced or metastatic breast cancer in adults whose tumours express PD ̶ level of 1% or more and who untreated PD-L1-positive, locally advanced or ‑ Surgery Oncology team (01/07/20). N/A response have not had previous chemotherapy for metastatic disease. It is recommended only if the company metastatic, triple-negative breast cancer provides atezolizumab according to the commercial arrangement. eligible patients to be referred to the Christie (TA639) x Hospital (07/07/20). MMC deemed N/A, added to the formulary for this indication, not stocked (13/08/20). Atezolizumab with carboplatin and etoposide 01/07/2020 Atezolizumab with carboplatin and etoposide ̶ recommended as an option for untreated extensive-stage 13/08/2020 43 Not on Trust formulary for this indication. N/A at for untreated extensive-stage small-cell lung small-cell lung cancer in adults, only if: ORC site for adults. Wythenshawe submitted fast • they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and cancer ( ) track application (07/07/20). Approved by MMC and TA638 • the company provides atezolizumab according to the commercial arrangement. x added to the formulary for this indication (13/08/20). Ranibizumab for treating diabetic retinopathy 30/06/2020 Ranibizumab ̶ NOT RECOMMENDED for treating diabetic retinopathy because Novartis did not provide 09/07/2020 9 Not on Trust formulary for this indication. (TA637) (TERMINATED APPRAISAL) an evidence submission. The company has confirmed that it does not intend to make a submission for the Terminated appraisal by NICE. MMC deemed N/A appraisal because it will not add value. Most people with proliferative diabetic retinopathy will also have diabetic macular oedema, and these people can already have ranibizumab in England and Wales (NICE (09/07/20). TA274). For people with proliferative diabetic retinopathy with no macular involvement, panretinal x photocoagulation is the preferred treatment. There is unlikely to be sufficient evidence that ranibizumab is a cost-effective use of NHS resources compared with panretinal photocoagulation.